# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...
Benchmark analyst Robert Wasserman reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 price target.
Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.
TD Cowen analyst Brendan Smith initiates coverage on Halozyme Therapeutics (NASDAQ:HALO) with a Outperform rating and announ...
JMP Securities analyst Jason Butler reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and maintains $7...
HC Wainwright & Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the pric...